Business
Update on licensing and development progress
Aptamer Group plc (AIM: APTA) announced multiple licensing opportunities and development progress. The company has received initial sales forecasts for its first commercial enzyme inhibitor, projected to cover approximately 15% of annual overhead via passive income over three years, with commercial sales anticipated before year-end. Licensing discussions are ongoing with a second partner, and a Material Transfer Agreement (MTA) was signed with a third, positioning the company for a potential third license. A second enzyme inhibitor project has reached the final development stage. Furthermore, a top-five pharmaceutical partner provided positive feedback on an Optimer® evaluation, resulting in repeat orders to support a clinical drug development program. These licensing agreements could generate hundreds of thousands of pounds in revenue. Disclaimer*
About this update from Aptamer Group Plc
[{"type":"text","content":"\n\n \n22 August 2025\n \nAptamer Group plc\n \n(\"Aptamer\", the \"Company\" or the \"Group\")\n \nUpdate on licensing and development progress\nMultiple enzyme modulation licensing opportunities and commercial validation from top five pharmaceutical partner\n \nAptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life sciences industry, is pleased to provide an update on its enzyme modulation projects and a separate development project with a top five pharmaceutical company, highlighting significant advancements in licensing and development.\n \nFirst enzyme-modulating Optimer® - multiple non-exclusive licensing opportunities\n \nAptamer's Optimer® binders modulate enzyme activity by specifically binding to the enzyme, changing its shape or blocking its active site, which can either inhibit or activate its function. This is commercially important because they enable precise, tunable control of enzyme activity, unlocking new possibilities for targeted therapeutics, diagnostics, molecular tools and industrial bioprocessing. The following license opportunities are related to exploitation in diagnostics and molecular tool applications.\n \n· Licence 1: Aptamer has received initial sales forecasts from its first partner for the first commercial enzyme inhibitor in one specific application area. This 10-year non-exclusive licensing deal, which is at an advanced stage of negotiation, is forecast to cover approximately 15% of the Group's annual overhead through passive income over the next three years. This forecast is subject to the partner achieving its projected sales targets, with commercial sales anticipated to begin before the end of the year.\n \n· Licence 2: Aptamer continues to advance licensing discussions with a second partner, a growing global distributor of enzymes for non-exclusive access to this enzyme-modulating product. Sales forecasts are currently being finalised for this second licensing agreement. Updates will be provided as discussions progress.\n \n· Licence 3: Aptamer has further signed a Material Transfer Agreement (MTA) with a third partner, a leading global distributor of enzymes, to allow this partner to evaluate the technology. This agreeme...